Heartflow, Inc. (NASDAQ:HTFL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Heartflow, Inc. (NASDAQ:HTFL) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $37.00.

A number of research firms have recently issued reports on HTFL. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Canaccord Genuity Group decreased their price objective on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 15th. William Blair initiated coverage on shares of Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock. Piper Sandler restated an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. Finally, Weiss Ratings cut Heartflow from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 8th.

Insiders Place Their Bets

In other news, CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $27.75, for a total value of $626,095.50. Following the transaction, the chief executive officer owned 435,373 shares in the company, valued at $12,081,600.75. This represents a 4.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares in the company, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,115,805 shares of company stock worth $62,445,744. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Heartflow

Several large investors have recently made changes to their positions in HTFL. Caitong International Asset Management Co. Ltd bought a new position in Heartflow during the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow during the 4th quarter worth $45,000. Legal & General Group Plc acquired a new position in shares of Heartflow during the 3rd quarter worth $59,000. Essential Partners LLC bought a new position in shares of Heartflow during the 1st quarter valued at $57,000. Finally, Strs Ohio bought a new stake in Heartflow in the fourth quarter worth $99,000.

Heartflow Stock Up 1.6%

Shares of NASDAQ HTFL opened at $24.61 on Friday. Heartflow has a 12 month low of $20.13 and a 12 month high of $41.22. The company has a market cap of $2.12 billion and a price-to-earnings ratio of -7.91. The business has a fifty day simple moving average of $29.33 and a 200-day simple moving average of $28.37.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.08. The company had revenue of $52.59 million for the quarter. The business’s quarterly revenue was up 41.3% on a year-over-year basis. As a group, sell-side analysts expect that Heartflow will post -0.82 EPS for the current fiscal year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.